Stage 1 of Essential hypertension
Conditions
Interventions
Treatment group 2:Oral Dugoupinggan Granules 10g/time, 3 times a day+nifedipine controlled-release tablets 30mg/time, once a day
Treatment group 1:Oral Dugoupinggan Granules 10g/time, 3 times a day
Model groups:Lifestyle guidance
Normal group:Lifestyle guidance
Control group:Oral nifedipine controlled-release tablets 30mg/time, once a day
Sponsors
The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Meet the diagnostic criteria for grade 1 essential hypertension in Western medicine; (2) Meet the diagnostic criteria of TCM Gan-Yang hyperactivity syndrome; (3) Age of onset: 18 years old= age = 65 years; (4) Those who agree to sign the informed consent form and cooperate with the collection of data and improve the relevant examinations.
Exclusion criteria
Exclusion criteria: (1) Patient has a systolic blood pressure = 160 mmHg and/or diastolic blood pressure = 100 mmHg; (2) Combined with severe cardiovascular and cerebrovascular diseases (such as cardiac insufficiency (New York cardiac function classification multi-grade III.) acute myocardial infarction cerebral hemorrhage cerebral infarction etc.); (3) Patients with secondary and malignant hypertension; (4) Peripheral vertigo (such as Meniere's disease positional vertigo etc.); (5) Central vertigo (such as vertigo caused by intracranial mass lesions and vascular lesions); (6) Oculogenic vertigo etc.; (7) Dizziness caused by cervical spondylosis etc.; (8) Severe liver and kidney damage blood diseases mental disorders malignant tumors and other diseases; (9) Patients with poor glycemic control of type I or type II diabetes mellitus (fasting blood glucose>11mmol/L); (10) Pregnant or lactating women; (11) Those who are intellectually or hearing impaired and unable to cooperate; (12) Patients who are allergic to the trial drug; (13)Other conditions that in the opinion of the investigator are not suitable for participation in this trial;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ambulatory blood pressure measurement; | — |
Secondary
| Measure | Time frame |
|---|---|
| Chinese medicine pattern score; | — |
Countries
China
Contacts
Public ContactDong Li
The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University
Outcome results
None listed